Literature DB >> 2869189

Analysis of the cardiovascular effects of co-derocrine (Hydergine).

B J Clark, T Bucher, R Waite.   

Abstract

The antihypertensive effect of co-dergocrine (Hydergine) has previously been thought to be due to alpha-adrenoceptor blockade and/or an action exerted in the CNS. The present experiments do not support this view. The doses necessary to inhibit vasoconstrictor responses to phenylephrine and noradrenaline by 50% in anaesthetized cats and dogs are 10-50 times that which lowers blood pressure in these species by 30 mmHg. Despite the fact that co-dergocrine is a potent alpha-adrenoceptor antagonist in isolated tissues (pA2: 8.4-9.4), its activity in vivo is too weak to contribute significantly to its effect on blood pressure. Slow intravertebral artery infusion of 10 micrograms/kg co-dergocrine produces a smaller blood pressure fall in the dog than intravenous infusion of the same dose. The reverse is true for the centrally-acting alpha 2-adrenoceptor stimulant, guanfacine. In addition, efferent splanchnic nerve activity in the cat is not affected by doses up to 100 micrograms/kg i.v. The dose of co-dergocrine depressing nerve activity by 50% is approximately 900 micrograms/kg; the dose of clonidine producing comparable inhibition is 3.4 micrograms/kg i.v. Since falls in blood pressure and heart rate can be obtained with co-dergocrine at a dose of only 10 micrograms/kg i.v., a central action cannot be considered to play a role in the cardiovascular effects of the drug in response to acute administration. Heart rate increases evoked by stimulating the accelerans nerve of ganglion-blocked cats are inhibited dose-dependently by co-dergocrine from a dose of 1 microgram/kg i.v. The drug also depresses pressor responses to stimulation of the lumbar sympathetic outflow in pithed rats. Both effects are prevented by pretreatment with the dopamine receptor antagonist, sulpiride (300 micrograms/kg). Intravenous administration of 10 micrograms/kg co-dergocrine depresses pressor responses to a psychological stimulus or raising the forequarters in conscious dogs, and produces marked falls in blood pressure and heart rate in anaesthetized, baroreceptor-denervated dogs. These effects are also abolished by sulpiride. It is concluded that the cardiovascular responses to acute administration of low doses of co-dergocrine are due to stimulation of prejunctional dopamine receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2869189

Source DB:  PubMed          Journal:  J Pharmacol        ISSN: 0021-793X


  4 in total

1.  Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function.

Authors:  W Kirch; A Nokhodian; A Halabi; G Weidinger
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

2.  Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension.

Authors:  R Kirsten; K Nelson; G Weidinger; D Welzel
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Reversal by the selective D-2 dopamine receptor blocker sulpiride of the hypotensive effect of co-dergocrine in elderly hypertensives.

Authors:  C Lombardi; R De Cotiis; C Spedini; C Missale; M Memo; P F Spano
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Inhibition of the aldosterone response to sodium depletion in man by stimulation of dopamine DA2 receptors.

Authors:  C Lombardi; C Missale; R De Cotiis; C Spedini; G Pizzoccolo; M Memo; A Albertini; P F Spano
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.